Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FIXXNASDAQ:KALANASDAQ:KMPHNASDAQ:VTGNOTCMKTS:WIZP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsKALAKALA BIO$5.29+4.8%$4.07$2.92▼$11.20$32.91M-1.8845,631 shs54,938 shsKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shsVTGNVistaGen Therapeutics$2.03-0.7%$2.28$1.90▼$4.21$58.32M0.61178,043 shs107,238 shsWIZPMawson Infrastructure Group$0.50+5.2%$0.55$0.07▼$1.45$466.87M1.77141,517 shs366,575 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFIXXHomology Medicines0.00%0.00%0.00%0.00%0.00%KALAKALA BIO0.00%+14.50%+26.86%+24.76%-22.43%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%VTGNVistaGen Therapeutics0.00%+2.79%-14.56%-13.83%-38.82%WIZPMawson Infrastructure Group+13.15%+28.18%-22.17%+21.71%-67.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFIXXHomology Medicines0.7426 of 5 stars0.00.00.04.80.60.80.6KALAKALA BIO3.3798 of 5 stars3.51.00.04.40.00.80.6KMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVTGNVistaGen Therapeutics1.3795 of 5 stars0.05.00.00.00.61.71.3WIZPMawson Infrastructure GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFIXXHomology Medicines 0.00N/AN/AN/AKALAKALA BIO 3.00Buy$13.50155.20% UpsideKMPHZevra Therapeutics 0.00N/AN/AN/AVTGNVistaGen Therapeutics 3.00BuyN/AN/AWIZPMawson Infrastructure Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KALA, FIXX, VTGN, WIZP, and KMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025VTGNVistaGen TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform6/2/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.005/23/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00KALAKALA BION/AN/AN/AN/A$2.02 per shareN/AKMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00VTGNVistaGen Therapeutics$486K121.49N/AN/A$2.44 per share0.83WIZPMawson Infrastructure GroupN/AN/AN/AN/A$0.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/AKALAKALA BIO-$38.51M-$8.24N/AN/AN/AN/A-369.29%-64.99%8/5/2025 (Estimated)KMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/AVTGNVistaGen Therapeutics-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/12/2025 (Estimated)WIZPMawson Infrastructure Group-$3.45M-$0.33N/AN/AN/AN/AN/A-85.32%N/ALatest KALA, FIXX, VTGN, WIZP, and KMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025VTGNVistaGen Therapeutics-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFIXXHomology MedicinesN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFIXXHomology MedicinesN/A7.257.25KALAKALA BIO3.191.991.99KMPHZevra Therapeutics0.1410.1010.10VTGNVistaGen TherapeuticsN/A6.516.51WIZPMawson Infrastructure GroupN/A1.131.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFIXXHomology Medicines31.32%KALAKALA BIO24.61%KMPHZevra Therapeutics19.39%VTGNVistaGen Therapeutics78.39%WIZPMawson Infrastructure GroupN/AInsider OwnershipCompanyInsider OwnershipFIXXHomology Medicines16.10%KALAKALA BIO8.32%KMPHZevra Therapeutics1.10%VTGNVistaGen Therapeutics1.29%WIZPMawson Infrastructure GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableKALAKALA BIO306.45 million5.92 millionNot OptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableVTGNVistaGen Therapeutics4029.16 million28.78 millionOptionableWIZPMawson Infrastructure Group2486.32 millionN/ANot OptionableKALA, FIXX, VTGN, WIZP, and KMPH HeadlinesRecent News About These CompaniesMawson Infrastructure Group (OTCMKTS:WIZP) Stock Price Down 0.2% - Should You Sell?June 18, 2025 | marketbeat.comH.C. Wainwright Sticks to Their Hold Rating for Mawson Infrastructure Group (MIGI)April 2, 2025 | markets.businessinsider.comMawson Infrastructure releases 2025 company presentationJanuary 28, 2025 | markets.businessinsider.comMawson Infrastructure names William Regan as CFOJanuary 17, 2025 | markets.businessinsider.comMawson Infrastructure reports December revenue $5.26M, up 7% month/monthJanuary 14, 2025 | markets.businessinsider.comMawson Infrastructure executes new customer agreementJanuary 7, 2025 | markets.businessinsider.comMawson Infrastructure Group Inc (MIGI) Stock Trading RecapDecember 10, 2024 | bovnews.comBCreditors file Chapter 11 involuntary petition against Mawson Infrastructure, latter vows to 'vigorously defend' itselfDecember 6, 2024 | bizjournals.comWhy Is Mawson Infrastructure Group Inc (MIGI) Stock Lagging Behind -56.76% from Its 50-Day SMA?December 6, 2024 | bovnews.comBMawson Infrastructure reports August revenue $4.44M; digital colocation business up 166% Y/YSeptember 16, 2024 | seekingalpha.comMawson Infrastructure Group Inc (MIGI) Stock: More Strategic Than Meets the EyeAugust 24, 2024 | bovnews.comBMawson Infra Gr (NASDAQ:MIGI) Stock, Short Interest ReportAugust 14, 2024 | benzinga.comMawson Infrastructure Group adds new customer at Midland bitcoin facilityDecember 20, 2023 | bizjournals.comMawson announces agreement for half of Midland bitcoin facility capacityOctober 19, 2023 | bizjournals.comMawson Infrastructure reports BTC production of 69 in July, down 3% M/MAugust 24, 2023 | seekingalpha.comH.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI)August 24, 2023 | markets.businessinsider.comMawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location ServicesJuly 25, 2023 | technews.tmcnet.comTMawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023July 19, 2023 | businesswire.comMawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023June 14, 2023 | technews.tmcnet.comTMawson Infrastructure Group names new president, CEOMay 22, 2023 | bizjournals.comWith Significant Increases In Megawatt Capacity And Bitcoin Production, Mawson Infrastructure Group (NASDAQ: MIGI) May Attract More Bitcoin Mining InvestorsApril 11, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALA, FIXX, VTGN, WIZP, and KMPH Company DescriptionsHomology Medicines NASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.KALA BIO NASDAQ:KALA$5.29 +0.24 (+4.75%) Closing price 07/3/2025 03:44 PM EasternExtended Trading$5.17 -0.12 (-2.34%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Zevra Therapeutics NASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.VistaGen Therapeutics NASDAQ:VTGN$2.02 -0.02 (-0.74%) Closing price 07/3/2025 03:33 PM EasternExtended Trading$2.03 +0.00 (+0.25%) As of 07/3/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.Mawson Infrastructure Group OTCMKTS:WIZP$0.50 +0.02 (+5.19%) As of 07/3/2025Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
